Literature DB >> 8163828

Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124.

A Li1, P D Cam, D Islam, N B Minh, P T Huan, Z C Rong, K Karlsson, G Lindberg, A A Lindberg.   

Abstract

The live, auxotrophic Shigella flexneri vaccine strain SFL124 was given in a single dose of 10(7), 10(8) or 10(9) colony forming units (cfu), respectively, to each of three groups of 10 Vietnamese children aged 9-14 years. The vaccine was well tolerated by all the children without any severe side effects such as diarrhoea or fever being observed. Mild symptoms were reported by five children. Only five children were found by culture to excrete SFL124 but, by PCR, 28 of 30 children were found to excrete the vaccine strain for up to 5 days (mean 2.8 days) with insignificant differences among the groups. Local mucosal immune responses and antibody secreting cell (ASC) responses to S. flexneri lipopolysaccharide (LPS) and invasion plasmid-coded antigens (Ipa) were elicited in the children in a dose-dependent manner. Doses of 10(9) cfu induced most prominent responses, followed by those of 10(8) and 10(7) cfu. The sIgA responses were the highest whereas the ASC were modest. High titres of serum antibodies to Shigella LPS and Ipa were found in all the children before ingestion of the vaccine which elicited increases in serum antibody titres in only a few of them. The immune response patterns seen indicate a booster rather than a primary response and may be a consequence of the endemic nature of shigellosis in Vietnam.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163828     DOI: 10.1016/s0163-4453(94)94006-1

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

3.  Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity.

Authors:  V Rasolofo-Razanamparany; A M Cassel-Beraud; J Roux; P J Sansonetti; A Phalipon
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Authors:  T S Coster; C W Hoge; L L VanDeVerg; A B Hartman; E V Oaks; M M Venkatesan; D Cohen; G Robin; A Fontaine-Thompson; P J Sansonetti; T L Hale
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

5.  Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.

Authors:  K R Turbyfill; S W Joseph; E V Oaks
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

6.  Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis.

Authors:  D Islam; B Wretlind; M Ryd; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

Review 7.  Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus.

Authors:  Jai K Das; Anjali Tripathi; Anum Ali; Amman Hassan; Chesarahima Dojosoeandy; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2013-09-17       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.